Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102

Neutropenia caused by TAS-102 during the first cycle was associated with better efficacy. Neutropenia may be a surrogate marker for adequate antitumor doses of TAS-102.